TrialDiabetes care2012

Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes.

Geremia B Bolli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.